Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(17)

Published: Feb. 26, 2024

As an indispensable part of the human sensory system, visual acuity may be impaired and even develop into irreversible blindness due to various ocular pathologies. Among diseases, fundus neovascularization diseases (FNDs) are prominent etiologies impairment worldwide. Intravitreal injection anti-vascular endothelial growth factor drugs remains primary therapy but is hurdled by common complications incomplete potency. To renovate current therapeutic modalities, nanomedicine emerged as times required, which endowed with advanced capabilities, able fulfill effective drug delivery achieve precise release control, thus further improving effect. This review provides a comprehensive summary advances in for FND management from state-of-the-art studies. First, modalities FNDs thoroughly introduced, focusing on key challenges delivery. Second, nanocarriers comprehensively reviewed posterior based nanostructures: polymer-based nanocarriers, lipid-based inorganic nanoparticles. Thirdly, characteristics microenvironment, their pathological changes during FNDs, corresponding strategies constructing smart elaborated. Furthermore, prospects discussed.

Language: Английский

---

Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(7), P. 2005 - 2005

Published: July 22, 2023

Retinal diseases are one of the leading causes blindness globally. The mainstay treatments for these blinding laser photocoagulation, vitrectomy, and repeated intravitreal injections anti-vascular endothelial growth factor (VEGF) or steroids. Unfortunately, therapies associated with ocular complications like inflammation, elevated intraocular pressure, retinal detachment, endophthalmitis, vitreous hemorrhage. Recent advances in nanomedicine seek to curtail limitations, overcoming barriers by developing non-invasive minimally invasive delivery modalities. These modalities include delivering therapeutics specific cellular targets retina, providing sustained drugs avoid injections, acting as a scaffold neural tissue regeneration. next-generation approaches could potentially revolutionize treatment landscape diseases. This review describes availability limitations current strategies highlights insights into advancement future using nanomedicines manage

Language: Английский

---

Nutraceuticals for Diabetic Retinopathy: Recent Advances and Novel Delivery Systems

Nutrients, Journal Year: 2024, Volume and Issue: 16(11), P. 1715 - 1715

Published: May 30, 2024

Diabetic retinopathy (DR) is a major vision-threatening disease among the working-age population worldwide. Present therapeutic strategies such as intravitreal injection of anti-VEGF and laser photocoagulation mainly target proliferative DR. However, there need for early effective management in patients with stage DR before its progression into more severe sight-threatening stage. Nutraceuticals, natural functional foods few side effects, have been proposed to be beneficial Over decades, many studies, either vitro or vivo, demonstrated advantages number nutraceuticals their antioxidative, anti-inflammatory, neuroprotective, vasoprotective effects. only clinical trials conducted, outcomes varied. The low bioavailability instability indeed hindered utilization use. In this context, nanoparticle carriers developed deliver improve bioavailability. Despite preclinical nature, research interventive may yield promising information applications.

Language: Английский

---

Ameliorating effect of the aldose reductase inhibitor 1-Acetyl-5-phenyl-1 H-pyrrol-3-ylacetate on galactose-induced cataract

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 14, 2025

Diabetes mellitus, as a common chronic disease, easily leads to significant changes in the structure of eye, among which diabetic cataract is particularly common. Although surgery main treatment for this complication, it may be accompanied by postoperative complications. Therefore, important develop specific drugs cataract, aiming fundamentally reduce its incidence and need surgery. At present, greatest challenge therapeutic agents with multiple synergistic effects based on complex pathogenesis cataract. 1-Acetyl-5-phenyl-1 H-pyrrol-3-ylacetate (APPA) designed pathological mechanism potential drug alleviate occurrence Our observations suggest that APPA more effective than bendazaclysine alleviating high galactose-induced oxidative stress (The malondialdehyde content group was significantly reduced 0.45-fold 0.58-fold compared group, respectively.) apoptosis rate 0.28-fold 0.35-fold lens epithelial cells increasing antioxidant enzyme activity, restoring mitochondrial homeostasis. Mechanistic studies have shown restoration homeostasis mediated through SIRT1-PGC-1α pathway. In rat model, conclusion, functions has wider range indications benzydalysine.

Language: Английский

---

Progressing nanotechnology to improve diagnosis and targeted therapy of Diabetic Retinopathy

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 183, P. 117786 - 117786

Published: Jan. 2, 2025

Language: Английский

---

Applications and latest research progress of liposomes in the treatment of ocular diseases

Biointerphases, Journal Year: 2025, Volume and Issue: 20(1)

Published: Jan. 1, 2025

The special structure of eyes and the existence various physiological barriers make ocular drug delivery one most difficult problems in pharmaceutical field. Considering patient compliance, local administration remains preferred method anterior part eyes. However, suffers from poor bioavailability, need for frequent administration, systemic toxicity. Administration posterior eye is more difficult, intravitreal injection often used. But faces compliance likely side effects after multiple injections. development nanocarrier technology provides an effective way to solve these problems. Among them, liposomes, as widely used carrier clinical application, have characteristics amphiphilic nanostructure, easy surface modification, extended release time, good biocompatibility, etc. liposomes are expected overcome obstacles effectively deliver drugs target site improve bioavailability. This review summarized controllable properties well application research progress diseases. In addition, we routes contained eyes, prospects treatment

Language: Английский

---

Frontier applications of retinal nanomedicine: progress, challenges and perspectives

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: Feb. 25, 2025

The human retina is a fragile and sophisticated light-sensitive tissue in the central nervous system. Unhealthy retinas can cause irreversible visual deterioration permanent vision loss. Effective therapeutic strategies are restricted to treatment or reversal of these conditions. In recent years, nanoscience nanotechnology have revolutionized targeted management retinal diseases. Pharmaceuticals, theranostics, regenerative medicine, gene therapy, prostheses indispensable for interventions been significantly advanced by nanomedical innovations. Hence, this review presents novel insights into use versatile nanomaterial-based nanocomposites frontier applications, including non-invasive drug delivery, theranostic contrast agents, nanoagents, stem cell-based optogenetics prostheses, which mainly reported within last 5 years. Furthermore, progress, potential challenges, future perspectives field highlighted discussed detail, may shed light on clinical translations ultimately, benefit patients with disorders.

Language: Английский

---

Topical Ocular Drug Delivery: The Impact of Permeation Enhancers

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(4), P. 447 - 447

Published: March 31, 2025

Topical ophthalmic drug delivery targeting the posterior segment of eye has become a key area interest due to its non-invasive nature, safety, ease application, patient compliance, and cost-effectiveness. However, achievement effective bioavailability in ocular is significant challenge unique barriers, including precorneal factors anatomical like cornea, conjunctiva, sclera. Successful systems require increased residence time improved corneal penetration enhance intraocular bioavailability. A promising strategy overcome these barriers incorporating enhancers (DPEs) into formulations. These compounds facilitate by improving permeability across otherwise impermeable or poorly permeable membranes. At level, they act through three primary mechanisms: breaking tear film stability interfering with mucous layer; disrupting membrane components such as phospholipids proteins; loosening epithelial cellular junctions. DPEs offer potential improve therapeutic outcomes, particularly for drugs eye. This review focused on analyzing current literature regarding use topical delivery, highlighting their mechanisms action revolutionize treatments.

Language: Английский

---

What do You Need to Know after Diabetes and before Diabetic Retinopathy?

Aging and Disease, Journal Year: 2025, Volume and Issue: unknown, P. 0 - 0

Published: Jan. 1, 2025

Diabetic retinopathy (DR) is a leading cause of vision impairment and blindness among individuals with diabetes mellitus. Current clinical diagnostic criteria mainly base on visible vascular structure changes, which are insufficient to identify diabetic patients without DR (NDR) but dysfunctional retinopathy. This review focuses retinal endothelial cells (RECs), the first sense respond elevated blood glucose. As glucose rises, RECs undergo compensatory transitional phases, correspondingly altered molecules likely become biomarkers targets for early prediction treatment NDR article elaborated possible pathophysiological processes focusing summarized recently published reliable screening emerging intervention strategies Additionally, references medication selection lifestyle recommendations this population provided. aims deepen understanding REC biology pathophysiology, emphasizes importance detection intervention, points out future directions improve diagnosis reduce occurrence DR.

Language: Английский

---

Reprogramming Retinal Microglia Polarization by Efferocytosis-Mimicking Nanoparticles for Ameliorating Diabetic Retinopathy

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: May 7, 2025

Diabetic retinopathy (DR), as the most common microvascular complication of diabetes, seriously threatens vision diabetic patients. As resident phagocytes retina, microglia participate in inflammation, neovascularization, and neurodegeneration DR. Herein, apoptotic retinal cell membrane-coated, rapamycin-loaded mesoporous Prussian blue NPs immunomodulators for ameliorating DR by modulating microglial polarization are reported. The apoM@mPB@Ra exhibited favorable stability biocompatibility achieved active targeted delivery due to specific recognition between "eat me" signal expressed on membrane microglia. In an LPS-induced cellular inflammation model, effectively promoted toward anti-inflammatory phenotype (M2) scavenging intracellular reactive oxygen species (ROS) combined with affecting mTOR signaling pathway, leading downregulation pro-inflammatory cytokines IL-6 TNF-α. Meanwhile, owing multienzyme-like activities mPB nanoparticles, obviously alleviated hypoxia, thereby decreasing expression VEGF. Notably, a mouse model DR, intravitreally injected significantly improved severity abnormal vascular network inflammatory microenvironment down-regulating HIF-1α, VEGF, inflammatory-related cytokines. Collectively, these findings demonstrate that provide promising effective approach treatment

Language: Английский

---